Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
13 studies found for:    tas-102
Show Display Options
Rank Status Study
1 Active, not recruiting Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Condition: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: Drug: TAS-102 tablets;   Drug: TAS-102 oral solution
2 Active, not recruiting Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102 with a light tracer dose of [14C]FTD;   Drug: TAS-102 with a light tracer dose of [14C] TPI;   Drug: TAS-102 tablets
3 Not yet recruiting A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
4 Recruiting Study of the Safety of Escalating Doses of TAS-102 in Combination With CPT-11 in Patients With Advanced Gastrointestinal Tumors
Condition: Advanced Gastrointestinal Tumors
Interventions: Drug: TAS-102;   Drug: CPT-11
5 Not yet recruiting A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Condition: Advanced Solid Tumors
Intervention: Drug: TAS-102
6 Active, not recruiting Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors (Excluding Breast Cancer)
Interventions: Drug: TAS-102;   Drug: Placebo
7 Active, not recruiting Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Condition: Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
8 Recruiting A Phase I Study of TAS-102 in Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Intervention: Drug: TAS-102
9 Active, not recruiting Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Condition: Advanced Solid Tumors
Interventions: Drug: TAS-102;   Drug: Trifluridine
10 Recruiting Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia
Condition: Colorectal Cancer
Interventions: Drug: TAS-102;   Drug: Placebo
11 Terminated A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Condition: Small Cell Lung Cancer (SCLC)
Interventions: Drug: TAS-102;   Drug: Amrubicin (Japan);   Drug: Topotecan (Japan/Europe)
12 Available Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Drug: TAS-102
13 Completed A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints
Conditions: Memory Disorders, Age-Related;   Retention Disorders, Cognitive
Interventions: Drug: EGb 761®  (Tanakan®);   Other: Placebo

Indicates status has not been verified in more than two years